A 3 months mild functional test regime does not affect disease parameters in young mdx mice

Neuromuscular Disorders

Volumn 20, Issue 4, 2010, Pages 273-280

  van Putten, Maaike ^a   de Winter, Christa ^a   van Roon Mom, Willeke ^a   van Ommen, Gert Jan ^a   't Hoen, Peter A C ^a   Aartsma Rus, Annemieke ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Biomarkers; Duchenne Muscular Dystrophy; Functional tests; Histopathology; Mdx mouse

Indexed keywords

CD68 ANTIGEN; CREATINE KINASE; GENE PRODUCT; GLUCOSE TRANSPORTER 4; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PROTEIN BGN; PROTEIN LGALS3; PROTEIN LOX; PROTEIN MYOG; PROTEIN TNNT2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 4; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIAPHRAGM; DISEASE COURSE; DISEASE MODEL; DUCHENNE MUSCULAR DYSTROPHY; FORELIMB; FUNCTIONAL ASSESSMENT; GENE EXPRESSION; GRIP STRENGTH; HANGING WIRE TEST; HEART; HISTOPATHOLOGY; MALE; MOTOR COORDINATION; MOUSE; MOUSE STRAIN; MUSCLE NECROSIS; MYOFIBROSIS; NONHUMAN; PRIORITY JOURNAL; REST; ROTAROD TEST; SKELETAL MUSCLE;

AGE FACTORS; ANIMALS; CREATINE KINASE; DISABILITY EVALUATION; DISEASE MODELS, ANIMAL; FIBROSIS; GENE EXPRESSION REGULATION; HEART; IMAGE PROCESSING, COMPUTER-ASSISTED; MALE; MICE; MICE, INBRED MDX; MOTOR ACTIVITY; MUSCLE FIBERS, SKELETAL; MUSCLE PROTEINS; MUSCLE STRENGTH; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; MYOCARDIUM; NEUROLOGIC EXAMINATION; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; RECOVERY OF FUNCTION; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 77950950164     PISSN: 09608966     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nmd.2010.02.004     Document Type: Article

References (28)

1. Hoffman E.P., Brown R.H., Kunkel L.M. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987, 51:919-928.
2. Blake D.J., Weir A., Newey S.E., Davies K.E. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 2002, 82:291-329.
3. Chen Y.W., Zhao P., Borup R., Hoffman E.P. Expression profiling in the muscular dystrophies: identification of novel aspects of molecular pathophysiology. J Cell Biol 2000, 151:1321-1336.
4. Whitehead N.P., Yeung E.W., Allen D.G. Muscle damage in mdx (dystrophic) mice: role of calcium and reactive oxygen species. Clin Exp Pharmacol Physiol 2006, 33:657-662.
5. Deconinck N., Dan B. Pathophysiology of Duchenne muscular dystrophy: current hypotheses. Pediatr Neurol 2007, 36:1-7.
6. Sicinski P., Geng Y., Ryder-Cook A.S., Barnard E.A., Darlison M.G., Barnard P.J. The molecular basis of muscular dystrophy in the mdx mouse: a point mutation. Science 1989, 244:1578-1580.
7. Grounds M.D., Radley H.G., Lynch G.S., Nagaraju K., De Luca A. Towards developing standard operating procedures for pre-clinical testing in the mdx mouse model of Duchenne muscular dystrophy. Neurobiol Dis 2008, 31:1-19.
8. Chamberlain J.S., Metzger J., Reyes M., Townsend D., Faulkner J.A. Dystrophin-deficient mdx mice display a reduced life span and are susceptible to spontaneous rhabdomyosarcoma. FASEB J 2007, 21:2195-2204.
9. Perkins K.J., Davies K.E. The role of utrophin in the potential therapy of Duchenne muscular dystrophy. Neuromuscul Disord 2002, 12(Suppl. 1):S78-S89.
10. De Luca A., Nico B., Rolland J.F., Cozzoli A., Burdi R., Mangieri D., et al. Gentamicin treatment in exercised mdx mice: identification of dystrophin-sensitive pathways and evaluation of efficacy in work-loaded dystrophic muscle. Neurobiol Dis 2008, 32:243-253.
11. Spurney C.F., Knoblach S., Pistilli E.E., Nagaraju K., Martin G.R., Hoffman E.P. Dystrophin-deficient cardiomyopathy in mouse: expression of Nox4 and Lox are associated with fibrosis and altered functional parameters in the heart. Neuromuscul Disord 2008, 18:371-381.
12. 't Hoen P.A., van der Wees C.G., Aartsma-Rus A., Turk R., Goyenvalle A., Danos O., et al. Gene expression profiling to monitor therapeutic and adverse effects of antisense therapies for Duchenne muscular dystrophy. Pharmacogenomics 2006, 7:281-297.
13. Dupont-Versteegden E.E., McCarter R.J., Katz M.S. Voluntary exercise decreases progression of muscular dystrophy in diaphragm of mdx mice. J Appl Physiol 1994, 77:1736-1741.
14. Radley H.G., Davies M.J., Grounds M.D. Reduced muscle necrosis and long-term benefits in dystrophic mdx mice after cV1q (blockade of TNF) treatment. Neuromuscul Disord 2008, 18:227-238.
15. Ruifrok A.C., Katz R.L., Johnston D.A. Comparison of quantification of histochemical staining by hue-saturation-intensity (HSI) transformation and color-deconvolution. Appl Immunohistochem Mol Morphol 2003, 11:85-91.
16. Connolly A.M., Keeling R.M., Mehta S., Pestronk A., Sanes J.R. Three mouse models of muscular dystrophy: the natural history of strength and fatigue in dystrophin-, dystrophin/utrophin-, and laminin alpha2-deficient mice. Neuromuscul Disord 2001, 11:703-712.
17. Turgeman T., Hagai Y., Huebner K., Jassal D.S., Anderson J.E., Genin O., et al. Prevention of muscle fibrosis and improvement in muscle performance in the mdx mouse by halofuginone. Neuromuscul Disord 2008, 18:857-868.
18. Baar K., Wende A.R., Jones T.E., Marison M., Nolte L.A., Chen M., et al. Adaptations of skeletal muscle to exercise: rapid increase in the transcriptional coactivator PGC-1. FASEB J 2002, 16:1879-1886.
19. Spurney C.F., Gordish-Dressman H., Guerron A.D., Sali A., Pandey G.S., Rawat R., et al. Preclinical drug trials in the mdx mouse: assessment of reliable and sensitive outcome measures. Muscle Nerve 2009, 39:591-602.
20. Willmann R., Possekel S., Dubach-Powell J., Meier T., Ruegg M.A. Mammalian animal models for Duchenne muscular dystrophy. Neuromuscul Disord 2009, 19:241-249.
21. Hayes A., Williams D.A. Contractile function and low-intensity exercise effects of old dystrophic (mdx) mice. Am J Physiol 1998, 274:C1138-C1144.
22. Carter G.T., Wineinger M.A., Walsh S.A., Horasek S.J., Abresch R.T., Fowler W.M. Effect of voluntary wheel-running exercise on muscles of the mdx mouse. Neuromuscul Disord 1995, 5:323-332.
23. De Luca A., Pierno S., Liantonio A., Cetrone M., Camerino C., Fraysse B., et al. Enhanced dystrophic progression in mdx mice by exercise and beneficial effects of taurine and insulin-like growth factor-1. J Pharmacol Exp Ther 2003, 304:453-463.
24. Granchelli J.A., Pollina C., Hudecki M.S. Pre-clinical screening of drugs using the mdx mouse. Neuromuscul Disord 2000, 10:235-239.
25. Faist V., Konig J., Hoger H., Elmadfa I. Decreased mitochondrial oxygen consumption and antioxidant enzyme activities in skeletal muscle of dystrophic mice after low-intensity exercise. Ann Nutr Metab 2001, 45:58-66.
26. Vilquin J.T., Brussee V., Asselin I., Kinoshita I., Gingras M., Tremblay J.P. Evidence of mdx mouse skeletal muscle fragility in vivo by eccentric running exercise. Muscle Nerve 1998, 21:567-576.
27. Golumbek P.T., Keeling R.M., Connolly A.M. Strength and corticosteroid responsiveness of mdx mice is unchanged by RAG2 gene knockout. Neuromuscul Disord 2007, 17:376-384.
28. Ishizaki M., Suga T., Kimura E., Shiota T., Kawano R., Uchida Y., et al. Mdx respiratory impairment following fibrosis of the diaphragm. Neuromuscul Disord 2008, 18:342-348.